Incyte PE ratio INCY

Share price divided by earnings per share over the last twelve months, since 2016.

Today, Oct 23, 2026: 14.7×
10-year median: 36.9×
Against its 10-year history: 4th; percentile: 0 is its lowest day, 100 its highest
10-year range: 13.5× to 497×
Peer median: 37.6×

Incyte's PE ratio is 14.7× as of Oct 23, 2026: a share price of $115.71 against $7.85 of earnings per share over the last twelve months.

That is below its ten-year median of 36.9×, lower than on 96% of days in the last ten years.

Over that time it ranged from 13.5× in May 2026 to 497× in Jan 2025.

The median for 10 biotech stocks of a similar size is 37.6×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	14.7×	13.5×	18.2×
2025	16.8×	15.7×	497×
2024	495×	16.1×	495×
2023	33.2×	20.6×	52.1×
2022	20.4×	15.6×	31.1×
2021	30.5×	26.8×	50.2×
2020	47.5×	32.7×	50.5×
2019	47.5×	44.9×	173×
2018	n/m a value too high to mean anything
2017	230×	139×	276×
2016	129×	112×	379×

Against its peers

Companies in Biotechnology nearest Incyte's size, closest first, today.

Company	PE ratio
INCYIncyte	14.7×
UTHRUnited Therapeutics	21.0×
ALNYAlnylam Pharmaceuticals	37.8×
EXELExelixis	20.3×
NBIXNeurocrine Biosciences	20.9×
HALOHalozyme Therapeutics	37.5×
ONCBeOne Medicines	67.6×
TECHBIO-TECHNE	63.1×
RGENRepligen	242×
KRYSKrystal Biotech	39.0×
REGNRegeneron Pharmaceuticals	19.9×
Peer median	37.6×

Where Incyte ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Incyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.